Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412139/
https://www.ncbi.nlm.nih.gov/pubmed/25647781
http://dx.doi.org/10.1093/jjco/hyv011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412139/
https://www.ncbi.nlm.nih.gov/pubmed/25647781
http://dx.doi.org/10.1093/jjco/hyv011

Ejemplares similares